CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.52-5.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Checking your notes…
| Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity | ||||||||
| Balance, September 30, 2023 | - | $ | - | 67,500,000 | $6,750 | $43,658,750 | $(18,129,840) | $25,535,660 |
| Capital contributions by parent | - | - | - | - | 37,008,905 | - | 37,008,905 | |
| Stock-based compensation expense | - | - | - | - | 7,498,817 | - | 7,498,817 | |
| Merger, net of transaction costs of $2,358,780 | - | - | 4,052,402 | 405 | (2,754,701) | - | (2,754,296) | |
| Net loss | - | - | - | - | - | (21,148,747) | (21,148,747) | |
| Balance, September 30, 2024 | - | - | 71,552,402 | 7,155 | 85,411,771 | (39,278,587) | 46,140,339 | |
| Issuance of common stock in July 2025 registered direct offering, net of costs of $1,453,012 | - | - | 6,818,182 | 682 | 7,546,306 | - | 7,546,988 | |
| Issuance of common stock in September 2025 registered direct offering, net of costs of $1,380,146 | - | - | 5,142,858 | 514 | 7,619,340 | - | 7,619,854 | |
| Stock-based compensation expense | - | - | - | - | 8,320,419 | - | 8,320,419 | |
| Net loss | - | - | - | - | - | (24,761,369) | (24,761,369) | |
| Balance, September 30, 2025 | - | $ | - | 83,513,442 | $8,351 | $108,897,836 | $(64,039,956) | $44,866,231 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.